Streamlining Access to CAR NK Clinical Manufacturing
Time: 12:00 pm
day: Day 2 - Track B- AM
Details:
- Key capabilities and infrastructure necessary to support clinical manufacturing of allogeneic CAR NK cell therapies
- The importance of a flexible manufacturing partner to support early phase cell therapy trials
- Pathways to reduce manufacturing cost to enable commercial supply for broader patient access
